Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours

Field	Value	Language
dc.contributor.author	Kanjanapan, Yada	en_AU
dc.contributor.author	Blinman, Prunella	en_AU
dc.contributor.author	Underhill, Craig	en_AU
dc.contributor.author	Karikios, Deme	en_AU
dc.contributor.author	Segelov, Eva	en_AU
dc.contributor.author	Yip, Desmond	en_AU
dc.date.accessioned	2021-07-06T23:34:20Z
dc.date.available	2021-07-06T23:34:20Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/25591
dc.description.abstract	People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.	en_AU
dc.language.iso	en	en_AU
dc.subject	COVID-19	en_AU
dc.subject	Coronavirus	en_AU
dc.title	Medical Oncology Group of Australia position statement: COVID‐19 vaccination in patients with solid tumours	en_AU
dc.type	Article	en_AU
dc.identifier.doi	10.1111/imj.15339

Associated file/s

There are no files associated with this item.